<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596100</url>
  </required_header>
  <id_info>
    <org_study_id>15-020</org_study_id>
    <nct_id>NCT02596100</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations</brief_title>
  <official_title>A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center open label randomized 4-period 2-sequence replicated crossover design
      study. A total of 52 healthy subjects will be randomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serial blood samples will be obtained for PK evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence analysis using total area under the curve (Total AUC) after a single dose of Betrixaban in healthy subjects</measure>
    <time_frame>120 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalance analysis using peak concentration in plasma (Cmax) after a single dose of Betrixaban in healthy volunteers</measure>
    <time_frame>120 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg immediate release tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg immediate release capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betrixaban</intervention_name>
    <arm_group_label>Tablet</arm_group_label>
    <arm_group_label>Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All inclusion criteria must be satisfied within 30 days of enrollment and must be
             documented in the source documents.

          -  A healthy man or woman between the ages of 18 and 60

          -  Has no clinically significant findings in medical history, physical examination, EKG
             and vital signs

          -  Weighs &gt; 45 kg (99 lbs.) and has body mass index (BMI) &lt; 30 kg/m2

          -  Agrees to abstain from alcohol consumption for 48 hrs prior to dosing and for the
             duration of each of the study in-house periods

          -  Is a non-smoker or light smoker (no more than the equivalent of five cigarettes per
             day) and agrees to abstain from smoking for the duration of each of the study in-house
             periods

        Exclusion Criteria:

          -  None of the exclusion criteria may be present for enrollment

          -  Known history (including family history) or symptoms of any clinically significant
             bleeding (i.e. a bleeding that required medical attention) or a vascular malformation

          -  Major surgery, severe trauma or bone fracture within 3 months of the first dose of the
             study drug or a planned surgery within 1 month after the last dose of the study drug

          -  History of blood donation of more than 500 mL within 3 months prior to the first dose
             of the study drug

          -  History of alcohol abuse (greater than 3 alcoholic beverages per day)

          -  Positive screen for drugs of abuse

          -  Positive serology test for HIV, Hepatitis B or C

          -  Has any allergy or sensitivity to fXa inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betrixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

